|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
JP5179689B2
(ja)
|
2000-02-11 |
2013-04-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗体ベース融合タンパク質の循環系内半減期の増強
|
|
CZ2003214A3
(cs)
|
2000-06-29 |
2003-08-13 |
Merck Patent Gmbh |
Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
|
|
ES2464532T3
(es)
|
2001-04-19 |
2014-06-03 |
The Scripps Research Institute |
Métodos y composiciones para la producción de pares ortogonales de ARNt-aminoacil-ARNt sintetasa
|
|
JP5275566B2
(ja)
|
2003-06-18 |
2013-08-28 |
ザ スクリプス リサーチ インスティチュート |
反応性非天然アミノ酸遺伝コード付加
|
|
WO2005019415A2
(en)
|
2003-07-07 |
2005-03-03 |
The Scripps Research Institute |
Compositions of orthogonal lysyl-trna and aminoacyl-trna synthetase pairs and uses thereof
|
|
WO2005007121A2
(en)
|
2003-07-18 |
2005-01-27 |
Massachusetts Institute Of Technology |
Mutant interleukin-2(il-2) polypeptides
|
|
US8147832B2
(en)
|
2003-08-14 |
2012-04-03 |
Merck Patent Gmbh |
CD20-binding polypeptide compositions and methods
|
|
NZ555308A
(en)
|
2004-12-22 |
2010-10-29 |
Ambrx Inc |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
|
AU2006332809A1
(en)
|
2005-12-30 |
2007-07-12 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
|
DE102008023820A1
(de)
|
2008-05-08 |
2009-11-12 |
Aicuris Gmbh & Co. Kg |
Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
|
|
WO2010085495A1
(en)
*
|
2009-01-21 |
2010-07-29 |
Amgen Inc. |
Compositions and methods of treating inflammatory and autoimmune diseases
|
|
EP2780463A4
(en)
|
2011-11-18 |
2015-07-01 |
Merck Sharp & Dohme |
FC-CONTAINING POLYPEPTIDES WITH INCREASED INFLAMMATORY FEATURES AND INCREASED FCRN BINDING
|
|
CA2858806A1
(en)
|
2011-12-23 |
2013-06-27 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
|
PL3489254T3
(pl)
|
2012-04-30 |
2023-01-30 |
Biocon Limited |
Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania
|
|
SI2890402T1
(sl)
|
2012-08-31 |
2019-07-31 |
Sutro Biopharma, Inc. |
Modificirane aminokisline vsebujoče acido skupino
|
|
EP3421495A3
(en)
|
2013-03-15 |
2019-05-15 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
EP3004062B1
(en)
|
2013-05-24 |
2017-07-19 |
SynAffix B.V. |
Substituted azadibenzocyclooctyne compounds and their use in metal-free click reactions
|
|
EP3650038A1
(en)
|
2013-06-19 |
2020-05-13 |
Massachusetts Institute of Technology |
In vivo targeting of cells with ligand-conjugated particles
|
|
KR20160042871A
(ko)
|
2013-06-21 |
2016-04-20 |
이나뜨 파르마, 에스.아. |
폴리펩티드의 효소적 콘쥬게이션
|
|
WO2015054658A1
(en)
|
2013-10-11 |
2015-04-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
|
EP3097080A1
(en)
|
2014-01-24 |
2016-11-30 |
SynAffix B.V. |
Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
|
|
PT3134123T
(pt)
|
2014-02-21 |
2021-03-22 |
Nektar Therapeutics India Pvt Ltd |
Agonistas seletivos de il-2rbeta em combinação com um anticorpo anti-ctla-4 ou um anticorpo anti-pd-1
|
|
JP6592505B2
(ja)
|
2014-04-24 |
2019-10-16 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
|
|
WO2016025647A1
(en)
|
2014-08-12 |
2016-02-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
|
|
WO2016115168A1
(en)
|
2015-01-12 |
2016-07-21 |
Synthorx, Inc. |
Incorporation of unnatural nucleotides and methods thereof
|
|
JP7299021B2
(ja)
|
2015-09-11 |
2023-06-27 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
生体関連の直交性サイトカイン/受容体ペア
|
|
RS62040B1
(sr)
*
|
2016-06-02 |
2021-07-30 |
Abbvie Inc |
Agonist receptora glukokortikoida i njegovi imunokonjugati
|
|
EP4631529A3
(en)
|
2016-06-28 |
2026-03-11 |
Ventana Medical Systems, Inc. |
Application of click chemistry for signal amplification in ihc and ish assays
|
|
EP3272864A1
(en)
|
2016-07-20 |
2018-01-24 |
Paul Scherrer Institut |
Solid-phase immobilization of microbial transglutaminase mtg on microbeads for protein conjugation
|
|
KR102461885B1
(ko)
|
2017-04-03 |
2022-11-03 |
에프. 호프만-라 로슈 아게 |
항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
|
|
KR20190136076A
(ko)
|
2017-04-13 |
2019-12-09 |
에프. 호프만-라 로슈 아게 |
암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
|
|
CA3061467A1
(en)
|
2017-04-28 |
2019-10-24 |
Ajinomoto Co., Inc. |
Compound having affinity substance to soluble protein, cleavable portionand reactive group, or salt thereof
|
|
US20200362058A1
(en)
|
2017-05-24 |
2020-11-19 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use
|
|
AU2018273914A1
(en)
|
2017-05-24 |
2019-11-14 |
Pandion Operations, Inc. |
Targeted immunotolerance
|
|
US20190023760A1
(en)
*
|
2017-07-24 |
2019-01-24 |
Eth Zurich |
Method for preparing interleukin-2 or interleukin-2 analogues
|
|
IL321812A
(en)
|
2017-08-03 |
2025-08-01 |
Synthorx Inc |
Cytokine complexes for the treatment of autoimmune diseases
|
|
AU2018337671B2
(en)
|
2017-09-19 |
2021-03-04 |
Paul Scherrer Institut |
Transglutaminase conjugation method and linker
|
|
KR102777151B1
(ko)
|
2017-11-21 |
2025-03-05 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
인터루킨-2의 부분 효능제
|
|
EP3720871A4
(en)
|
2017-12-06 |
2021-09-15 |
Pandion Operations, Inc. |
TARGETED IMMUNOTOLERANCE
|
|
JP7765181B2
(ja)
|
2017-12-19 |
2025-11-06 |
ゼンコア インコーポレイテッド |
改変されたil-2 fc融合タンパク質
|
|
US11970537B2
(en)
|
2017-12-26 |
2024-04-30 |
Nanjing GenScript Biotech Co., Ltd. |
Fusion protein dimer using antibody Fc region as backbone and use thereof
|
|
JP7102670B2
(ja)
|
2018-01-25 |
2022-07-20 |
アイ-エムエービー バイオファーマ ユーエス リミテッド |
抗pd‐l1抗体とil‐7との融合
|
|
CA3115461A1
(en)
|
2018-03-09 |
2019-09-12 |
AskGene Pharma, Inc. |
Novel cytokine prodrugs
|
|
WO2019185792A1
(en)
|
2018-03-29 |
2019-10-03 |
Philogen S.P.A |
Cancer treatment using immunoconjugates and immune check-point inhibitors
|
|
CN108503714A
(zh)
|
2018-04-10 |
2018-09-07 |
浙江科途医学科技有限公司 |
一种人白介素2和抗人上皮细胞黏附分子单链抗体融合蛋白及其应用
|
|
EP4406975A3
(en)
|
2018-06-14 |
2024-11-13 |
Ajinomoto Co., Inc. |
Compound having affinity substance to antibody and bioorthogonal functional group, or salt thereof
|
|
JP7413999B2
(ja)
|
2018-06-14 |
2024-01-16 |
味の素株式会社 |
抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
|
|
AU2019288496B2
(en)
|
2018-06-22 |
2024-11-21 |
Cugene Inc. |
Interleukin-2 variants and methods of uses thereof
|
|
US12522640B2
(en)
|
2018-07-24 |
2026-01-13 |
BioNTech SE |
IL2 agonists
|
|
WO2020061142A1
(en)
|
2018-09-18 |
2020-03-26 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
CA3117853A1
(en)
|
2018-10-29 |
2020-05-07 |
1Globe Biomedical Co., Ltd. |
Novel rationally designed protein compositions
|
|
JPWO2020090979A1
(ja)
|
2018-10-31 |
2021-09-24 |
味の素株式会社 |
抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
|
|
TW202034945A
(zh)
|
2018-12-21 |
2020-10-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
一種人白細胞介素2變體或其衍生物
|
|
CN113613679A
(zh)
|
2019-03-19 |
2021-11-05 |
保罗·谢勒学院 |
基于甘氨酸的接头的转谷氨酰胺酶缀合方法
|
|
KR20220009380A
(ko)
|
2019-05-17 |
2022-01-24 |
선전 엔듀어링 바이오테크 리미티드 |
표적 면역요법을 위한 절단 가능한 사이토카인이 있는 이중특이적 t-세포 연계체
|
|
AU2020279240A1
(en)
*
|
2019-05-20 |
2021-12-23 |
Pandion Operations, Inc. |
MAdCAM targeted immunotolerance
|
|
AU2020285636A1
(en)
*
|
2019-05-24 |
2021-11-04 |
Proviva Therapeutics (Hong Kong) Limited |
IL-2 compositions and methods of use thereof
|
|
WO2020252421A2
(en)
*
|
2019-06-14 |
2020-12-17 |
Cugene, Inc. |
Novel interleukin-2 variants and bifunctional fusion molecules thereof
|
|
KR20260089650A
(ko)
*
|
2019-07-12 |
2026-06-15 |
프로비바 테라퓨틱스 (홍콩) 리미티드 |
Il-2 조성물 및 이의 사용 방법
|
|
PH12022550165A1
(en)
*
|
2019-07-26 |
2023-05-08 |
Visterra Inc |
Interleukin-2 agents and uses thereof
|
|
EP4013775A1
(en)
|
2019-08-12 |
2022-06-22 |
Askgene Pharma, Inc. |
Il-2 fusion proteins that preferentially bind il-2ralpha
|
|
AU2020329933A1
(en)
|
2019-08-15 |
2022-03-24 |
Cytimm Therapeutics, Inc. |
Modified interleukin 2 (IL-2) polypeptides, conjugates and uses thereof
|
|
CN110642934B
(zh)
|
2019-09-10 |
2022-08-23 |
中国医学科学院北京协和医院 |
靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用
|
|
JP2022552371A
(ja)
*
|
2019-10-15 |
2022-12-15 |
モデルナティエックス インコーポレイテッド |
免疫調節ポリペプチドをコードするmRNA及びその使用
|
|
AU2020403148A1
(en)
*
|
2019-12-13 |
2022-06-30 |
Cugene Inc. |
Cytokine-based bioactivatable drugs and methods of uses thereof
|
|
US11648296B2
(en)
|
2019-12-13 |
2023-05-16 |
Synthekine, Inc. |
IL-2 orthologs and methods of use
|
|
TW202136287A
(zh)
|
2019-12-17 |
2021-10-01 |
法商Ose免疫治療公司 |
包含il-7變體之雙官能分子
|
|
IL293978A
(en)
|
2019-12-20 |
2022-08-01 |
Regeneron Pharma |
New il2 agonists and methods of using them
|
|
CA3162320A1
(en)
|
2019-12-23 |
2021-07-01 |
Alexander V. SHIROKOV |
Methods of preparing n6-((2-azidoethoxy)carbonyl)lysine
|
|
KR20220140514A
(ko)
|
2020-01-10 |
2022-10-18 |
브라이트 피크 테라퓨틱스 아게 |
변형된 il-2 폴리펩타이드 및 그의 용도
|
|
CN115362168A
(zh)
|
2020-01-14 |
2022-11-18 |
辛德凯因股份有限公司 |
偏向化il2突变蛋白方法和组合物
|
|
AR121713A1
(es)
|
2020-03-31 |
2022-06-29 |
Hanmi Pharm Ind Co Ltd |
Nuevos análogos de il-2 inmunoestimulantes
|
|
CA3168460A1
(en)
|
2020-04-15 |
2021-10-21 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
|
KR102986821B1
(ko)
|
2020-04-22 |
2026-07-06 |
머크 샤프 앤드 돔 엘엘씨 |
인터류킨-2 수용체 베타 감마c 이량체에 대해 편향되고 비펩티드성 수용성 중합체에 접합된 인간 인터류킨-2 접합체
|
|
EP4143329A4
(en)
|
2020-04-28 |
2024-10-16 |
Anwita Biosciences, Inc. |
Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
|
|
AU2021402065A1
(en)
|
2020-12-17 |
2023-06-29 |
Boehringer Ingelheim International Gmbh |
Bifunctional anti-pd1/il-7 molecules
|
|
WO2022140797A1
(en)
|
2020-12-23 |
2022-06-30 |
Immunowake Inc. |
Immunocytokines and uses thereof
|
|
JP2024504372A
(ja)
|
2021-01-22 |
2024-01-31 |
エルピス・バイオファーマシューティカルズ |
抗pd-l1モノクローナル抗体及びインターロイキン15(il-15)、インターロイキン15受容体15アルファまたはインターロイキン2との融合タンパク質
|